Literature DB >> 31621397

AHNAK Nucleoprotein 2 Performs a Promoting Role in the Proliferation and Migration of Uveal Melanoma Cells.

Mengyun Li1, Yanchen Liu1, Yanling Meng2, Yan Zhu3.   

Abstract

AHNAK nucleoprotein 2 (AHNAK2) is supposed to participate in calcium signaling and cytoarchitecture by directly interacting with some proteins. Recently, it was identified as a novel candidate oncogene in human tumors. The author's present study aimed to investigate the expression and biological function of AHNAK2 in uveal melanoma (UM). Based on microarray data of 63 UM patients that were downloaded from Gene Expression Omnibus database, the authors found that AHNAK2 expression is higher in UM primary tumor tissues from patients who developed metastases after enucleation than that in UM primary tumor tissues from patients without metastasis after enucleation. On the basis of the data obtained from The Cancer Genome Atlas database, they found that high AHNAK2 expression is closely associated with shorter overall survival time in UM patients. From quantitative reverse transcription polymerase chain reaction analyses, they revealed that the mRNA expression level of AHNAK2 was significantly upregulated in M17 and SP6.5 cell lines compared with that in D78. Functionally, knockdown of AHNAK2 using small interfering RNA in M17 and SP6.5 cells dramatically suppressed cell proliferation, migratory and invasive abilities, as well as inhibited the activation of phosphatidylinositol 3-kinase (PI3K) signaling pathway. Taken together, their results illustrated that AHNAK2 was upregulated in UM and plays a promoting role in the proliferation and migration of UM cells possibly via regulating PI3K signaling pathway.

Entities:  

Keywords:  AHNAK2; PI3K; migration; proliferation; uveal melanoma

Mesh:

Substances:

Year:  2019        PMID: 31621397     DOI: 10.1089/cbr.2019.2778

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  8 in total

1.  Integrative Proteo-Genomic Analysis for Recurrent Survival Prognosis in Colon Adenocarcinoma.

Authors:  FeiYan Ai; Wenhao Wang; Shaojun Liu; Decai Zhang; Zhenyu Yang; Fen Liu
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

2.  AHNAK2 Is Associated with Poor Prognosis and Cell Migration in Lung Adenocarcinoma.

Authors:  Shusen Zhang; Yuanyuan Lu; Lei Qi; Hongyan Wang; Zhihua Wang; Zhigang Cai
Journal:  Biomed Res Int       Date:  2020-08-20       Impact factor: 3.411

3.  AHNAK2 Promotes Migration, Invasion, and Epithelial-Mesenchymal Transition in Lung Adenocarcinoma Cells via the TGF-β/Smad3 Pathway.

Authors:  Gang Liu; Zhongliang Guo; Qian Zhang; Zhongmin Liu; Dongyi Zhu
Journal:  Onco Targets Ther       Date:  2020-12-16       Impact factor: 4.147

4.  Construction and Validation of a Novel Immunosignature for Overall Survival in Uveal Melanoma.

Authors:  Chufeng Gu; Xin Gu; Yujie Wang; Zhixian Yao; Chuandi Zhou
Journal:  Front Cell Dev Biol       Date:  2021-09-06

Review 5.  The Obscure Potential of AHNAK2.

Authors:  Mohamed Zardab; Konstantinos Stasinos; Richard P Grose; Hemant M Kocher
Journal:  Cancers (Basel)       Date:  2022-01-21       Impact factor: 6.639

6.  Construction of a Redox-Related Prognostic Model with Predictive Value in Survival and Therapeutic Response for Patients with Lung Adenocarcinoma.

Authors:  Lingyan Xiao; Qian Li; Yongbiao Huang; Zhijie Fan; Li Ma; Bo Liu; Xianglin Yuan
Journal:  J Healthc Eng       Date:  2022-02-25       Impact factor: 2.682

7.  Deimination Protein Profiles in Alligator mississippiensis Reveal Plasma and Extracellular Vesicle-Specific Signatures Relating to Immunity, Metabolic Function, and Gene Regulation.

Authors:  Michael F Criscitiello; Igor Kraev; Lene H Petersen; Sigrun Lange
Journal:  Front Immunol       Date:  2020-04-28       Impact factor: 7.561

8.  Down-Regulation of AHNAK2 Inhibits Cell Proliferation, Migration and Invasion Through Inactivating the MAPK Pathway in Lung Adenocarcinoma.

Authors:  Dong-Wei Wang; Hai-Zheng Zheng; Na Cha; Xiao-Jie Zhang; Min Zheng; Ming-Ming Chen; Li-Xiang Tian
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.